Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Ashland Buying International Specialty Products for $3.2B

By Pharmaceutical Processing | May 31, 2011

 

COVINGTON,
Kentucky (AP) — Ashland Inc. will
spend about $3.2 billion to buy International Specialty Products Inc., the
company said Tuesday, expanding its presence in high-growth markets including
personal care, pharmaceutical and energy.

Ashland
is just the latest entity to snap up a high-margin specialty chemical company,
following Berkshire Hathaway’s $9 billion acquisition of Lubrizol, and Dow
Chemical’s $15 billion buyout of Rohm & Haas.

The latest deal, expected to close before the end of the
fourth quarter, should immediately add to Ashland’s
earnings per share. The transaction is expected to save Ashland approximately $50 million by the
second year after the acquisition’s closing by eliminating redundancies and
making operations more efficient.

The deal “broadens Ashland’s presence within attractive growth
areas like skin, hair and oral care, which are large and fast-growing segments
of the $5-billion-plus personal care specialty ingredients market,” said
Chairman and CEO James O’Brien.

The company will more than double the size of its our
highest-margin functional ingredients business, O’Brien said.

The Covington,
Kentucky, chemical company plans
to use available cash and committed financing from several banks including
Citi, The Bank of Nova Scotia, Bank of America Merrill Lynch and U.S. Bank
National Association.

If financing falls through, ISP could require Ashland to pay a $413
million termination fee.

The deal requires U.S. and European Union regulatory
approvals.

ISP, based in Wayne,
New Jersey, had approximately
$1.6 billion in sales for the year ended March 31.

 

Related Articles Read More >

Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE